HRP20090009T3 - N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
HRP20090009T3
HRP20090009T3 HR20090009T HRP20090009T HRP20090009T3 HR P20090009 T3 HRP20090009 T3 HR P20090009T3 HR 20090009 T HR20090009 T HR 20090009T HR P20090009 T HRP20090009 T HR P20090009T HR P20090009 T3 HRP20090009 T3 HR P20090009T3
Authority
HR
Croatia
Prior art keywords
alkyl
aryl
group
heteroaryl
substituted
Prior art date
Application number
HR20090009T
Other languages
English (en)
Croatian (hr)
Inventor
R. V. Finlay Maurice
Waterson David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20090009T3 publication Critical patent/HRP20090009T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20090009T 2003-06-27 2009-01-08 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors HRP20090009T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20090009T3 true HRP20090009T3 (en) 2009-02-28

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090009T HRP20090009T3 (en) 2003-06-27 2009-01-08 N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (34)

Country Link
US (1) US7485644B2 (ar)
EP (1) EP1644340B1 (ar)
JP (1) JP4701167B2 (ar)
KR (1) KR20060026440A (ar)
CN (2) CN1812974B (ar)
AR (1) AR044931A1 (ar)
AT (1) ATE414063T1 (ar)
AU (1) AU2004251104B2 (ar)
BR (1) BRPI0411929A (ar)
CA (1) CA2529468A1 (ar)
CO (1) CO5650254A2 (ar)
CY (1) CY1108757T1 (ar)
DE (1) DE602004017733D1 (ar)
DK (1) DK1644340T3 (ar)
ES (1) ES2315675T3 (ar)
HK (1) HK1086835A1 (ar)
HR (1) HRP20090009T3 (ar)
IL (1) IL172615A0 (ar)
IS (1) IS8257A (ar)
MX (1) MXPA05013460A (ar)
MY (1) MY138680A (ar)
NO (1) NO20060444L (ar)
NZ (1) NZ544208A (ar)
PL (1) PL1644340T3 (ar)
PT (1) PT1644340E (ar)
RU (1) RU2351595C2 (ar)
SA (1) SA04250224B1 (ar)
SE (1) SE0301922D0 (ar)
SI (1) SI1644340T1 (ar)
TW (1) TW200524898A (ar)
UA (1) UA81491C2 (ar)
UY (1) UY28387A1 (ar)
WO (1) WO2005000822A1 (ar)
ZA (1) ZA200510458B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CN101346353B (zh) * 2005-10-26 2012-01-11 默克雪兰诺有限公司 磺酰胺衍生物及其在调节金属蛋白酶中的用途
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2592154T3 (es) * 2010-07-08 2016-11-28 Kaken Pharmaceutical Co., Ltd. Derivado de N-hidroxiformamida y medicamento que contiene el mismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100266A (en) * 1998-01-30 2000-08-08 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CA2374460A1 (en) * 1999-06-04 2000-12-14 Astrazeneca Ab Inhibitors of metalloproteinases
CA2396965C (en) * 2000-02-21 2010-03-16 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004113312A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
CY1108757T1 (el) 2014-04-09
RU2351595C2 (ru) 2009-04-10
SE0301922D0 (sv) 2003-06-27
IS8257A (is) 2006-01-23
MXPA05013460A (es) 2006-03-09
DE602004017733D1 (de) 2008-12-24
EP1644340A1 (en) 2006-04-12
HK1086835A1 (en) 2006-09-29
PL1644340T3 (pl) 2009-04-30
EP1644340B1 (en) 2008-11-12
SI1644340T1 (sl) 2009-02-28
PT1644340E (pt) 2009-01-02
AR044931A1 (es) 2005-10-12
TW200524898A (en) 2005-08-01
WO2005000822A1 (en) 2005-01-06
US7485644B2 (en) 2009-02-03
BRPI0411929A (pt) 2006-08-15
ES2315675T3 (es) 2009-04-01
US20070197542A1 (en) 2007-08-23
UA81491C2 (en) 2008-01-10
DK1644340T3 (da) 2009-02-02
CO5650254A2 (es) 2006-06-30
KR20060026440A (ko) 2006-03-23
RU2005141058A (ru) 2006-07-27
IL172615A0 (en) 2006-04-10
MY138680A (en) 2009-07-31
CN1812974B (zh) 2011-06-29
ATE414063T1 (de) 2008-11-15
CA2529468A1 (en) 2005-01-06
AU2004251104B2 (en) 2008-05-08
JP2007516164A (ja) 2007-06-21
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
UY28387A1 (es) 2005-01-31
CN102229589A (zh) 2011-11-02
JP4701167B2 (ja) 2011-06-15
AU2004251104A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
HRP20090009T3 (en) N-{'4-substituted piperazine-1-sulfonylmethyl]alkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
RS52313B (en) MYTHOSIS PROGRESS INHIBITION UNITS
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RS52326B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
HRP20080120T3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
RS53061B (en) INHIBITORI PROTEIN KINAZE
RS50045B (sr) Aktivatori glukokinaze
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
RS52546B (en) 1H-BENZIMIDAZOL-4-CARBOXAMIDES SUBSTITUTED WITH QUATERNERN CARBON AT POSITION-2 ARE POWERFUL PARP INHIBITORS
RS52100B (en) PROCEDURES AND UNITS FOR PREPARING ANALOG CC-1065
BRPI0506817A (pt) inibidores seletivos de quinase
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
CO5011090A1 (es) Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos
RS51193B (sr) Hidantoinski derivati korisni kao inhibitori metaloproteinaza
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
YU39698A (sh) Hinoksalindioni
ME00981B (me) 1,2,4,5-tetrahidr0-3h-benzazepinska jedinjenja, postupak za njihovu izradu i smješe koje ih sadrže
HRP20080431T3 (en) Novel dicarboxylic acid derivatives
FI832648A (fi) Dihydropyridiner som antiischemiska och antihypertensiva laekemedel
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
BR112022002674A2 (pt) Derivado de 2-aminoquinazolinona
RS51320B (sr) Derivati imidazohinolina kao veznici a3 receptora adenozina